Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia

Initial One-Year Exclusivity Period Will Be Extended to Three Years if Endari is Approved for Marketing

TORRANCE, Calif., Jan. 29, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its Endari® (L-glutamine oral powder) has been afforded market exclusivity in the Kingdom of Saudi Arabia, or KSA, by the National Uniform Procurement Agency, or NUPCO (NUPCO Tender No. 014/24 COMPLIMENTARY PHARMA TENDER January 09, 2025).  NUPCO, KSA's unified purchasing system, extends to all KSA government institutions, including hospitals under the Ministry of Health, Military Hospitals, the National Guard, the Security Forces, and King Faisal Specialty Hospitals and Research Centers.

Read more at prnewswire.com